Skip to main content
Top
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Gastric Cancer | Review

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis

Authors: Mohammad Reza Eskandarion, Sharareh Eskandarieh, Sara Tutunchi, Abbas Shakoori Farahani, Reza Shirkoohi

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Investigating the role of circulating tumor cells (CTCs) and their characteristics is still controversial in patients with gastric cancer (GC). Therefore, in this study, to provide a comprehensive review and meta-analyses of the literature on association of CTCs with gastric cancer, Scopus, Web of Science, Embase, and Medline were searched for systematic reviews and meta-analyses conducted during February 2022 using the keywords. Risk of bias, hazard ratios (HRs), and risk differences (RD) were assessed. Forty-five studies containing 3,342 GC patients from nine countries were assessed. The overall prevalence of CTC in GC was 69.37% (60.27, 77.78). The pooled result showed that increased mortality in GC patients was significantly associated with positive CTCs, poor overall survival (HR = 2.73, 95%CI 2.34–3.24, p < 0.001), and progression-free survival rate (HR = 2.78, 95%CI 2.01–3.85, p < 0.001). Subgroup analyses regarding markers, detection methods, treatment type, presence of distance metastasis, presence of lymph node metastasis, and overall risk of bias showed significant associations between the groups in terms of the incidence rates of CTCs, OS, and PFS. In addition, the results of risk differences based on sampling time showed that the use of the cell search method (RD: − 0.19, 95%CI (− 0.28, − 0.10), p < 0.001), epithelial marker (RD: − 0.12, 95%CI (− 0.25, 0.00), p 0.05) and mesenchymal markers (RD: − 0.35, 95%CI (− 0.57, − 0.13), p 0.002) before the treatment might have a higher diagnostic power to identify CTCs and also chemotherapy treatment (RD: − 0.17, 95%CI (− 0.31, − 0.03), p 0.016) could significantly reduce the number of CTCs after the treatment. We also found that the risk differences between the clinical early and advanced stages were not statistically significant (RD: − 0.10, 95%CI (− 0.23, 0.02), P 0.105). Also, in the Lauren classification, the incidence of CTC in the diffuse type (RD: − 0.19, 95%CI (− 0.37, − 0.01), P0.045) was higher than that in the intestinal type. Meta-regression analysis showed that baseline characteristics were not associated with the detection of CTCs in GC patients. According to our systematic review and meta-analysis, CTCs identification may be suggested as a diagnostic technique for gastric cancer screening, and the outcomes of CTC detection may also be utilized in the future to create personalized medicine programs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68(6):394–424. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68(6):394–424.
2.
go back to reference Akbarpour E, Sadjadi A, Derakhshan M, Roshandel G, Alimohammadian M. Gastric cancer in Iran: an overview of risk factors and preventive measures. Arch Iran Med. 2021;24(7):556–67.PubMedCrossRef Akbarpour E, Sadjadi A, Derakhshan M, Roshandel G, Alimohammadian M. Gastric cancer in Iran: an overview of risk factors and preventive measures. Arch Iran Med. 2021;24(7):556–67.PubMedCrossRef
3.
go back to reference Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. The Lancet. 2009;374(9688):477–90.CrossRef Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. The Lancet. 2009;374(9688):477–90.CrossRef
4.
go back to reference Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20(2):226–34.PubMedCrossRef Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20(2):226–34.PubMedCrossRef
5.
go back to reference Zhao Z, Yin Z, Wang S, Wang J, Bai B, Qiu Z, et al. Meta-analysis: the diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol. 2016;31(9):1539–45.PubMedCrossRef Zhao Z, Yin Z, Wang S, Wang J, Bai B, Qiu Z, et al. Meta-analysis: the diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol. 2016;31(9):1539–45.PubMedCrossRef
6.
go back to reference Europe P, Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20:13842–62.CrossRef Europe P, Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20:13842–62.CrossRef
7.
go back to reference Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33.PubMedCrossRef Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33.PubMedCrossRef
8.
go back to reference Paget S. The distribution of secondary growths in cancer of the breast. The Lancet. 1889;133(3421):571–3.CrossRef Paget S. The distribution of secondary growths in cancer of the breast. The Lancet. 1889;133(3421):571–3.CrossRef
9.
go back to reference De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, et al. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Ther Adv Med Oncol. 2019;11:1758835919866065.PubMedPubMedCentralCrossRef De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, et al. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Ther Adv Med Oncol. 2019;11:1758835919866065.PubMedPubMedCentralCrossRef
10.
go back to reference Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, et al. Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. Cancers. 2020;12(2):487.PubMedPubMedCentralCrossRef Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, et al. Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. Cancers. 2020;12(2):487.PubMedPubMedCentralCrossRef
11.
go back to reference Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, White E, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg. 2010;136(12):1274–9. Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, White E, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg. 2010;136(12):1274–9.
12.
go back to reference Zhou S, Wang L, Zhang W, Liu F, Zhang Y, Jiang B, et al. Circulating tumor cells correlate with prognosis in head and neck squamous cell carcinoma. Technol Cancer Res Treat. 2021;20:1533033821990037.PubMedPubMedCentralCrossRef Zhou S, Wang L, Zhang W, Liu F, Zhang Y, Jiang B, et al. Circulating tumor cells correlate with prognosis in head and neck squamous cell carcinoma. Technol Cancer Res Treat. 2021;20:1533033821990037.PubMedPubMedCentralCrossRef
13.
go back to reference Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients–a prospective study. BMC Cancer. 2017;17(1):1–11.CrossRef Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients–a prospective study. BMC Cancer. 2017;17(1):1–11.CrossRef
14.
go back to reference Wang L, Zhou S, Zhang W, Wang J, Wang M, Hu X, et al. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients. Int J Colorectal Dis. 2019;34(4):589–97.PubMedCrossRef Wang L, Zhou S, Zhang W, Wang J, Wang M, Hu X, et al. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients. Int J Colorectal Dis. 2019;34(4):589–97.PubMedCrossRef
15.
go back to reference Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–31.PubMedCrossRef Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–31.PubMedCrossRef
16.
go back to reference Nakamura K, Iwatsuki M, Kurashige J, Ishimoto T, Baba Y, Miyamoto Y, et al. Circulating tumor cells in gastric cancer. J Cancer Metastasis Treat. 2018;4:32.CrossRef Nakamura K, Iwatsuki M, Kurashige J, Ishimoto T, Baba Y, Miyamoto Y, et al. Circulating tumor cells in gastric cancer. J Cancer Metastasis Treat. 2018;4:32.CrossRef
17.
go back to reference Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem cells. 2009;27(5):1006–20.PubMedCrossRef Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem cells. 2009;27(5):1006–20.PubMedCrossRef
18.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). J Chin Integr Med. 2009;7(9):889–96. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). J Chin Integr Med. 2009;7(9):889–96.
19.
go back to reference Rupp B, Ball H, Wuchu F, Nagrath D, Nagrath S. Circulating tumor cells in precision medicine: challenges and opportunities. Trends Pharmacol Sci. 2022. Rupp B, Ball H, Wuchu F, Nagrath D, Nagrath S. Circulating tumor cells in precision medicine: challenges and opportunities. Trends Pharmacol Sci. 2022.
20.
go back to reference Wang S, Zheng G, Cheng B, Chen F, Wang Z, Chen Y, et al. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature. PLoS ONE. 2014;9(6): e99259.PubMedPubMedCentralCrossRef Wang S, Zheng G, Cheng B, Chen F, Wang Z, Chen Y, et al. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature. PLoS ONE. 2014;9(6): e99259.PubMedPubMedCentralCrossRef
21.
go back to reference Huang X, Gao P, Sun J, Chen X, Song Y, Zhao J, et al. Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: a meta-analysis. Int J Cancer. 2015;136(1):21–33.PubMedCrossRef Huang X, Gao P, Sun J, Chen X, Song Y, Zhao J, et al. Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: a meta-analysis. Int J Cancer. 2015;136(1):21–33.PubMedCrossRef
22.
go back to reference Tang L, Zhao S, Liu W, Parchim NF, Huang J, Tang Y, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13(1):1–15.CrossRef Tang L, Zhao S, Liu W, Parchim NF, Huang J, Tang Y, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13(1):1–15.CrossRef
23.
go back to reference Zou K, Yang S, Zheng L, Wang S, Xiong B. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer: a meta-analysis. BioMed Res Int. 2016;2016. Zou K, Yang S, Zheng L, Wang S, Xiong B. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer: a meta-analysis. BioMed Res Int. 2016;2016.
24.
go back to reference Gao Y, Xi H, Wei B, Cui J, Zhang K, Li H, et al. Association between liquid biopsy and prognosis of gastric cancer patients: a systematic review and meta-analysis. Front Oncol. 2019;9:1222.PubMedPubMedCentralCrossRef Gao Y, Xi H, Wei B, Cui J, Zhang K, Li H, et al. Association between liquid biopsy and prognosis of gastric cancer patients: a systematic review and meta-analysis. Front Oncol. 2019;9:1222.PubMedPubMedCentralCrossRef
25.
go back to reference Wang H-Y, Wei J, Zou Z-Y, Qian X-P, Liu B-R. Circulating tumour cells predict survival in gastric cancer patients: a meta-analysis. Contemp Oncol/Współczesna Onkologia. 2015;19(6):451–7.PubMedCrossRef Wang H-Y, Wei J, Zou Z-Y, Qian X-P, Liu B-R. Circulating tumour cells predict survival in gastric cancer patients: a meta-analysis. Contemp Oncol/Współczesna Onkologia. 2015;19(6):451–7.PubMedCrossRef
26.
go back to reference Yang C, Zou K, Yuan Z, Guo T, Xiong B. Prognostic value of circulating tumor cells detected with the Cell Search System in patients with gastric cancer: evidence from a meta-analysis. Onco Targets Ther. 2018;11:1013.PubMedPubMedCentralCrossRef Yang C, Zou K, Yuan Z, Guo T, Xiong B. Prognostic value of circulating tumor cells detected with the Cell Search System in patients with gastric cancer: evidence from a meta-analysis. Onco Targets Ther. 2018;11:1013.PubMedPubMedCentralCrossRef
27.
go back to reference Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org. 2011. Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www cochrane-handbook org. 2011.
28.
go back to reference Higgins J. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions, version 51 0. 2011. Higgins J. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions, version 51 0. 2011.
29.
go back to reference Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–26.PubMedCrossRef Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–26.PubMedCrossRef
30.
go back to reference Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M. Trials. 2007. Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M. Trials. 2007.
31.
go back to reference Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef
32.
go back to reference Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–51.PubMedCrossRef Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–51.PubMedCrossRef
33.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
34.
go back to reference Asimit J, Day-Williams A, Zgaga L, Rudan I, Boraska V, Zeggini E. An evaluation of different meta-analysis approaches in the presence of allelic heterogeneity. Eur J Hum Genet. 2012;20(6):709–12.PubMedPubMedCentralCrossRef Asimit J, Day-Williams A, Zgaga L, Rudan I, Boraska V, Zeggini E. An evaluation of different meta-analysis approaches in the presence of allelic heterogeneity. Eur J Hum Genet. 2012;20(6):709–12.PubMedPubMedCentralCrossRef
35.
go back to reference Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRef
36.
go back to reference Duval S. The trim and fill method. Publication bias in meta-analysis: Prevention, assessment and adjustments. 2005:127–44. Duval S. The trim and fill method. Publication bias in meta-analysis: Prevention, assessment and adjustments. 2005:127–44.
37.
go back to reference Chen Y, Li Y, Qi C, Zhang C, Liu D, Deng Y, et al. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. Cancer Lett. 2021;517:78–87.PubMedCrossRef Chen Y, Li Y, Qi C, Zhang C, Liu D, Deng Y, et al. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. Cancer Lett. 2021;517:78–87.PubMedCrossRef
38.
go back to reference Chen Y, Yuan J, Li Y, Li X, Yang Y, Li J, et al. Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer. Hum Cell. 2021;34(5):1446–54.PubMedPubMedCentralCrossRef Chen Y, Yuan J, Li Y, Li X, Yang Y, Li J, et al. Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer. Hum Cell. 2021;34(5):1446–54.PubMedPubMedCentralCrossRef
39.
go back to reference Abdallah EA, Braun AC, Flores BC, Senda L, Urvanegia AC, Calsavara V, et al. The potential clinical implications of circulating tumor cells and circulating tumor microemboli in gastric cancer. Oncologist. 2019;24(9):e854–63.PubMedPubMedCentralCrossRef Abdallah EA, Braun AC, Flores BC, Senda L, Urvanegia AC, Calsavara V, et al. The potential clinical implications of circulating tumor cells and circulating tumor microemboli in gastric cancer. Oncologist. 2019;24(9):e854–63.PubMedPubMedCentralCrossRef
40.
go back to reference Zheng X, Fan L, Zhou P, Ma H, Huang S, Yu D, et al. Detection of circulating tumor cells and circulating tumor microemboli in gastric cancer. Transl Oncol. 2017;10(3):431–41.PubMedPubMedCentralCrossRef Zheng X, Fan L, Zhou P, Ma H, Huang S, Yu D, et al. Detection of circulating tumor cells and circulating tumor microemboli in gastric cancer. Transl Oncol. 2017;10(3):431–41.PubMedPubMedCentralCrossRef
41.
go back to reference Lee SJ, Lee J, Kim ST, Park SH, Park JO, Park YS, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Mark. 2015;30(4):382–6.CrossRef Lee SJ, Lee J, Kim ST, Park SH, Park JO, Park YS, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Mark. 2015;30(4):382–6.CrossRef
42.
go back to reference Jhi JH, Kim GH, Park SJ, Kim DU, Lee MW, Lee BE, et al. Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer: a preliminary study. J Clin Med. 2021;10(19):4481.PubMedPubMedCentralCrossRef Jhi JH, Kim GH, Park SJ, Kim DU, Lee MW, Lee BE, et al. Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer: a preliminary study. J Clin Med. 2021;10(19):4481.PubMedPubMedCentralCrossRef
43.
go back to reference Yu P, Zhu S, Luo Y, Li G, Pu Y, Cai B, et al. Application of circulating tumor cells and circulating free DNA from peripheral blood in the prognosis of advanced gastric cancer. J Oncol. 2022;2022. Yu P, Zhu S, Luo Y, Li G, Pu Y, Cai B, et al. Application of circulating tumor cells and circulating free DNA from peripheral blood in the prognosis of advanced gastric cancer. J Oncol. 2022;2022.
44.
go back to reference Qian C, Cai R, Zhang W, Wang J, Hu X, Zhang Y, et al. Neutrophil-lymphocyte ratio and circulating tumor cells counts predict prognosis in gastrointestinal cancer patients. Front Oncol 2021;11. Qian C, Cai R, Zhang W, Wang J, Hu X, Zhang Y, et al. Neutrophil-lymphocyte ratio and circulating tumor cells counts predict prognosis in gastrointestinal cancer patients. Front Oncol 2021;11.
45.
go back to reference Matsushita D, Uenosono Y, Arigami T, Yanagita S, Okubo K, Kijima T, et al. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer. Cancer Chemother Pharmacol. 2021;87(6):789–97.PubMedCrossRef Matsushita D, Uenosono Y, Arigami T, Yanagita S, Okubo K, Kijima T, et al. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer. Cancer Chemother Pharmacol. 2021;87(6):789–97.PubMedCrossRef
46.
go back to reference Ishiguro Y, Sakihama H, Yoshida T, Ichikawa N, Homma S, Fukai M, et al. Prognostic significance of circulating tumor cells with mesenchymal phenotypes in patients with gastric cancer: a prospective study. Ann Surg Oncol. 2021;28(2):1178–86.PubMedCrossRef Ishiguro Y, Sakihama H, Yoshida T, Ichikawa N, Homma S, Fukai M, et al. Prognostic significance of circulating tumor cells with mesenchymal phenotypes in patients with gastric cancer: a prospective study. Ann Surg Oncol. 2021;28(2):1178–86.PubMedCrossRef
47.
go back to reference Zhu Y, Chen N, Chen M, Cui X, Yang H, Zhu X, et al. Circulating tumor cells: A surrogate to predict the effect of treatment and overall survival in gastric adenocarcinoma. Int J Biol Mark. 2021;36(1):28–35.CrossRef Zhu Y, Chen N, Chen M, Cui X, Yang H, Zhu X, et al. Circulating tumor cells: A surrogate to predict the effect of treatment and overall survival in gastric adenocarcinoma. Int J Biol Mark. 2021;36(1):28–35.CrossRef
48.
go back to reference Ning D, Cui K, Liu M, Ou Y, Wang Z, Zou B, et al. Comparison of cell search and circulating tumor cells (CTC)-biopsy systems in detecting peripheral blood circulating tumor cells in patients with gastric cancer. Med Sci Monit Int Med J Exp Clin Res. 2021;27:e926565–71. Ning D, Cui K, Liu M, Ou Y, Wang Z, Zou B, et al. Comparison of cell search and circulating tumor cells (CTC)-biopsy systems in detecting peripheral blood circulating tumor cells in patients with gastric cancer. Med Sci Monit Int Med J Exp Clin Res. 2021;27:e926565–71.
49.
go back to reference Kuroda K, Yashiro M, Miki Y, Sera T, Yamamoto Y, Sugimoto A, et al. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor. Cancer Sci. 2020;111(12):4500–9.PubMedPubMedCentralCrossRef Kuroda K, Yashiro M, Miki Y, Sera T, Yamamoto Y, Sugimoto A, et al. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor. Cancer Sci. 2020;111(12):4500–9.PubMedPubMedCentralCrossRef
50.
go back to reference Liu M, Wang R, Sun X, Liu Y, Wang Z, Yan J, et al. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Mol Oncol. 2020;14(4):865–81.PubMedPubMedCentralCrossRef Liu M, Wang R, Sun X, Liu Y, Wang Z, Yan J, et al. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Mol Oncol. 2020;14(4):865–81.PubMedPubMedCentralCrossRef
51.
go back to reference Hu B, Tian X, Li Y, Liu Y, Yang T, Han Z, et al. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. Cancer Med. 2020;9(8):2686–97.PubMedPubMedCentralCrossRef Hu B, Tian X, Li Y, Liu Y, Yang T, Han Z, et al. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. Cancer Med. 2020;9(8):2686–97.PubMedPubMedCentralCrossRef
52.
go back to reference Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z, et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer. Onco Targets Ther. 2019;12:7887.PubMedPubMedCentralCrossRef Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z, et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer. Onco Targets Ther. 2019;12:7887.PubMedPubMedCentralCrossRef
53.
go back to reference Lu R, Chen Q, Liu X, Shen S, Pan Z, Shi C. Detection of circulating stage III–IV gastric cancer tumor cells based on isolation by size of epithelial tumor: using the circulating tumor cell biopsy technology. Transl Cancer Res. 2019;8(4):1342.PubMedPubMedCentralCrossRef Lu R, Chen Q, Liu X, Shen S, Pan Z, Shi C. Detection of circulating stage III–IV gastric cancer tumor cells based on isolation by size of epithelial tumor: using the circulating tumor cell biopsy technology. Transl Cancer Res. 2019;8(4):1342.PubMedPubMedCentralCrossRef
54.
go back to reference Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, et al. Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. Cancer Biol Ther. 2019;20(4):546–51.PubMedCrossRef Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, et al. Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. Cancer Biol Ther. 2019;20(4):546–51.PubMedCrossRef
55.
go back to reference Li Y, Ma G, Zhao P, Fu R, Gao L, Jiang X, et al. Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH. Clin Chim Acta. 2018;485:95–102.PubMedCrossRef Li Y, Ma G, Zhao P, Fu R, Gao L, Jiang X, et al. Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH. Clin Chim Acta. 2018;485:95–102.PubMedCrossRef
56.
go back to reference Zhang Q, Shan F, Li Z, Gao J, Li Y, Shen L, et al. A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. J Transl Med. 2018;16(1):1–12.CrossRef Zhang Q, Shan F, Li Z, Gao J, Li Y, Shen L, et al. A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. J Transl Med. 2018;16(1):1–12.CrossRef
57.
go back to reference Szczepanik A, Sierzega M, Drabik G, Pituch-Noworolska A, Kołodziejczyk P, Zembala M. CD44+ cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosis of patients with gastric cancer. Gastric Cancer. 2019;22(2):264–72.PubMedCrossRef Szczepanik A, Sierzega M, Drabik G, Pituch-Noworolska A, Kołodziejczyk P, Zembala M. CD44+ cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosis of patients with gastric cancer. Gastric Cancer. 2019;22(2):264–72.PubMedCrossRef
58.
go back to reference Li Y, Zhang X, Liu D, Gong J, Wang DD, Li S, et al. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res. 2018;24(21):5261–71.PubMedCrossRef Li Y, Zhang X, Liu D, Gong J, Wang DD, Li S, et al. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res. 2018;24(21):5261–71.PubMedCrossRef
59.
go back to reference Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 2017;12(3):341–51.PubMedCrossRef Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 2017;12(3):341–51.PubMedCrossRef
60.
go back to reference Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer. 2017;17(1):1–9.CrossRef Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer. 2017;17(1):1–9.CrossRef
61.
go back to reference Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer. 2017;79:15–22.PubMedCrossRef Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer. 2017;79:15–22.PubMedCrossRef
62.
go back to reference Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang Y, et al. Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Mol Clin Oncol. 2017;6(2):235–42.PubMedPubMedCentralCrossRef Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang Y, et al. Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Mol Clin Oncol. 2017;6(2):235–42.PubMedPubMedCentralCrossRef
63.
go back to reference Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh M, et al. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World J Gastroenterol. 2018;24(7):810.PubMedPubMedCentralCrossRef Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh M, et al. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World J Gastroenterol. 2018;24(7):810.PubMedPubMedCentralCrossRef
64.
go back to reference Zheng L, Zou K, Yang C, Chen F, Guo T, Xiong B. Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients. Clin Transl Oncol. 2017;19(9):1125–32.PubMedCrossRef Zheng L, Zou K, Yang C, Chen F, Guo T, Xiong B. Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients. Clin Transl Oncol. 2017;19(9):1125–32.PubMedCrossRef
65.
go back to reference Kang HM, Kim GH, Jeon HK, Kim DH, Jeon TY, Park DY, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer. PLoS ONE. 2017;12(6): e0180251.PubMedPubMedCentralCrossRef Kang HM, Kim GH, Jeon HK, Kim DH, Jeon TY, Park DY, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer. PLoS ONE. 2017;12(6): e0180251.PubMedPubMedCentralCrossRef
66.
go back to reference Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, et al. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chin J Cancer Res. 2016;28(6):579.PubMedCentralCrossRef Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, et al. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chin J Cancer Res. 2016;28(6):579.PubMedCentralCrossRef
67.
go back to reference Ito H, Sato J, Tsujino Y, Yamaguchi N, Kimura S, Gohda K, et al. Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World J Gastroenterol. 2016;22(46):10232.PubMedPubMedCentralCrossRef Ito H, Sato J, Tsujino Y, Yamaguchi N, Kimura S, Gohda K, et al. Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World J Gastroenterol. 2016;22(46):10232.PubMedPubMedCentralCrossRef
68.
go back to reference Yuan D, Chen L, Li M, Xia H, Zhang Y, Chen T, et al. Isolation and characterization of circulating tumor cells from human gastric cancer patients. J Cancer Res Clin Oncol. 2015;141(4):647–60.PubMedCrossRef Yuan D, Chen L, Li M, Xia H, Zhang Y, Chen T, et al. Isolation and characterization of circulating tumor cells from human gastric cancer patients. J Cancer Res Clin Oncol. 2015;141(4):647–60.PubMedCrossRef
69.
go back to reference Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncol Lett. 2017;13(1):281–8.PubMedCrossRef Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncol Lett. 2017;13(1):281–8.PubMedCrossRef
70.
go back to reference Kolostova K, Matkowski R, Gürlich R, Grabowski K, Soter K, Lischke R, et al. Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology. 2016;68(4):1095–102.PubMedCrossRef Kolostova K, Matkowski R, Gürlich R, Grabowski K, Soter K, Lischke R, et al. Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology. 2016;68(4):1095–102.PubMedCrossRef
71.
go back to reference Li Y, Gong J, Zhang Q, Lu Z, Gao J, Li Y, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114(2):138–45.PubMedPubMedCentralCrossRef Li Y, Gong J, Zhang Q, Lu Z, Gao J, Li Y, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114(2):138–45.PubMedPubMedCentralCrossRef
72.
go back to reference Okabe H, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22(12):3954–61.PubMedCrossRef Okabe H, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22(12):3954–61.PubMedCrossRef
73.
go back to reference Li T-T, Liu H, Li F-P, Hu Y-F, Mou T-Y, Lin T, et al. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: relevance to therapy response. World J Gastroenterol. 2015;21(47):13259.PubMedPubMedCentralCrossRef Li T-T, Liu H, Li F-P, Hu Y-F, Mou T-Y, Lin T, et al. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: relevance to therapy response. World J Gastroenterol. 2015;21(47):13259.PubMedPubMedCentralCrossRef
74.
go back to reference Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T, et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 2015;137(4):991–8.PubMedCrossRef Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T, et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 2015;137(4):991–8.PubMedCrossRef
75.
go back to reference Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stölzel U. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2015;89(5):294–303.PubMedCrossRef Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stölzel U. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2015;89(5):294–303.PubMedCrossRef
76.
go back to reference Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014;5(16):6594.PubMedPubMedCentralCrossRef Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014;5(16):6594.PubMedPubMedCentralCrossRef
77.
go back to reference Li M, Zhang B, Zhang Z, Liu X, Qi X, Zhao J, et al. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. BioMed Res Int. 2014;2014. Li M, Zhang B, Zhang Z, Liu X, Qi X, Zhao J, et al. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. BioMed Res Int. 2014;2014.
78.
go back to reference Iwatsuki M, Toyoshima K, Watanabe M, Hayashi N, Ishimoto T, Eto K, et al. Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br J Cancer. 2013;109(11):2829–32.PubMedPubMedCentralCrossRef Iwatsuki M, Toyoshima K, Watanabe M, Hayashi N, Ishimoto T, Eto K, et al. Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br J Cancer. 2013;109(11):2829–32.PubMedPubMedCentralCrossRef
79.
go back to reference Uenosono Y, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119(22):3984–91.PubMedCrossRef Uenosono Y, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119(22):3984–91.PubMedCrossRef
80.
go back to reference Ito H, Inoue H, Sando N, Kimura S, Gohda K, Sato J, et al. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer. 2012;12(1):1–10.CrossRef Ito H, Inoue H, Sando N, Kimura S, Gohda K, Sato J, et al. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer. 2012;12(1):1–10.CrossRef
81.
go back to reference Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101(4):1067–71.PubMedCrossRef Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101(4):1067–71.PubMedCrossRef
82.
go back to reference Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–50.PubMedPubMedCentral Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–50.PubMedPubMedCentral
83.
go back to reference Hou J-M, Krebs M, Ward T, Sloane R, Priest L, Hughes A, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011;178(3):989–96.PubMedPubMedCentralCrossRef Hou J-M, Krebs M, Ward T, Sloane R, Priest L, Hughes A, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011;178(3):989–96.PubMedPubMedCentralCrossRef
84.
go back to reference Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008;26(8):1208–15.PubMedCrossRef Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008;26(8):1208–15.PubMedCrossRef
85.
go back to reference Takeuchi H, Kitagawa Y. Circulating tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat Sci. 2010;17(5):577–82.PubMedCrossRef Takeuchi H, Kitagawa Y. Circulating tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat Sci. 2010;17(5):577–82.PubMedCrossRef
86.
go back to reference Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13(1):395–412.PubMedCrossRef Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13(1):395–412.PubMedCrossRef
87.
go back to reference Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(9):e386–95.PubMedCrossRef Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(9):e386–95.PubMedCrossRef
88.
go back to reference Liu Y, Li Q, Chen T, Shen T, Zhang X, Song P, et al. Clinical verification of vimentin/EpCAM immunolipid magnetic sorting system in monitoring CTCs in arterial and venous blood of advanced tumor. J Nanobiotechnol. 2021;19(1):1–16.CrossRef Liu Y, Li Q, Chen T, Shen T, Zhang X, Song P, et al. Clinical verification of vimentin/EpCAM immunolipid magnetic sorting system in monitoring CTCs in arterial and venous blood of advanced tumor. J Nanobiotechnol. 2021;19(1):1–16.CrossRef
90.
go back to reference Negishi R, Yamakawa H, Kobayashi T, Horikawa M, Shimoyama T, Koizumi F, et al. Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer. Communications biology. 2022;5(1):1–12.CrossRef Negishi R, Yamakawa H, Kobayashi T, Horikawa M, Shimoyama T, Koizumi F, et al. Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer. Communications biology. 2022;5(1):1–12.CrossRef
Metadata
Title
Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis
Authors
Mohammad Reza Eskandarion
Sharareh Eskandarieh
Sara Tutunchi
Abbas Shakoori Farahani
Reza Shirkoohi
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-024-01310-6

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine